Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 2.83 USD -5.67% Market Closed
Market Cap: 254.5m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one EDIT stock under the Base Case scenario is 1.09 USD. Compared to the current market price of 2.83 USD, Editas Medicine Inc is Overvalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EDIT Relative Value
Base Case
1.09 USD
Overvaluation 61%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.4
P/S
P/S
Price to Sales
6.4
vs History
71
vs Industry
69
Median 3Y
8.6
Median 5Y
27.2
Industry
7.6
Forward
14
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-3.9
Industry
24.5
Forward
-1.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4.5
Industry
21
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-4.3
Industry
23.5
More Details
12.9
P/B
P/B
Price to Book Value
12.9
vs History
0
vs Industry
64
Median 3Y
1.8
Median 5Y
2.2
Industry
3.1
More Details
3.1
EV/S
EV/S
Enterprise Value to Sales
3.1
vs History
69
vs Industry
72
Median 3Y
4.4
Median 5Y
13.5
Industry
8.1
Forward
6.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
24
Median 3Y
-1.1
Median 5Y
-1.7
Industry
5.7
Forward
-0.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
22
Median 3Y
-1
Median 5Y
-1.6
Industry
6.1
Forward
-0.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
26
Median 3Y
-1.4
Median 5Y
-2.1
Industry
7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
22
Median 3Y
-1.4
Median 5Y
-2
Industry
5.3
More Details
4.8
EV/IC
EV/IC
Enterprise Value to IC
4.8
vs History
30
vs Industry
61
Median 3Y
1.9
Median 5Y
3.2
Industry
5.3
More Details

Multiples Across Competitors

EDIT Competitors Multiples
Editas Medicine Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Editas Medicine Inc
NASDAQ:EDIT
247.3m USD 6.4 -1 -0.8 -0.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 651 194.5 -159 939.1 -194 217.1 -192 000.9
US
Abbvie Inc
NYSE:ABBV
393B USD 6.7 105.6 17.2 24.9
US
Amgen Inc
NASDAQ:AMGN
153.6B USD 4.4 23.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
141.7B USD 4.9 22.5 10.5 14.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 093.5 -534.2 -581.7 -566.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
98.2B USD 8.6 27 19.8 20.7
AU
CSL Ltd
ASX:CSL
96.1B AUD 4.1 21.1 14 17.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
63B USD 4.4 14.1 12.7 14.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.4B USD 24.1 -186.2 -465.5 -319.5
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
US
Editas Medicine Inc
NASDAQ:EDIT
Average P/S: 3 059 397.4
6.4
-23%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 651 194.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
4%
1.2
US
E
Epizyme Inc
F:EPE
2 093.5
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.6
10%
0.9
AU
CSL Ltd
ASX:CSL
4.1
6%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
5%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.1
41%
0.6
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Editas Medicine Inc
NASDAQ:EDIT
Average P/E: 35.6
Negative Multiple: -1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 939.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
105.6
88%
1.2
US
Amgen Inc
NASDAQ:AMGN
23.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
6%
2.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -186.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Editas Medicine Inc
NASDAQ:EDIT
Average EV/EBITDA: 15.4
Negative Multiple: -0.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
19.8
17%
1.2
AU
CSL Ltd
ASX:CSL
14
10%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -465.5 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Editas Medicine Inc
NASDAQ:EDIT
Average EV/EBIT: 18.4
Negative Multiple: -0.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 000.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.4
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.7
17%
1.2
AU
CSL Ltd
ASX:CSL
17.5
14%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
12%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -319.5 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A

See Also

Summary
EDIT intrinsic value, competitors valuation, and company profile.
DCF Valuation
EDIT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EDIT stock valuation using valuation multiples.
Wall Street Estimates
EDIT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EDIT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 283,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.